Pfizer, Biocon abort alliance as business differences outweigh [bio]similarities
This article was originally published in Scrip
Pfizer and Biocon have aborted their alliance for biosimilar versions of insulin and insulin analogue products, though the Indian firm says that the separation is unlikely to hurt its near-term earnings. Both erstwhile partners said that in view of their "individual priorities" for their respective biosimilars businesses they would now move ahead independently.
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.